NO763196L - PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES. - Google Patents

PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES.

Info

Publication number
NO763196L
NO763196L NO763196A NO763196A NO763196L NO 763196 L NO763196 L NO 763196L NO 763196 A NO763196 A NO 763196A NO 763196 A NO763196 A NO 763196A NO 763196 L NO763196 L NO 763196L
Authority
NO
Norway
Prior art keywords
benzimidazole
carbomethoxyamino
phenylsulfonyloxy
acid chloride
benzenesulfonic acid
Prior art date
Application number
NO763196A
Other languages
Norwegian (no)
Inventor
Heinz Loewe
Josef Urbanietz
Dieter Duewel
Reinhard Kirsch
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO763196L publication Critical patent/NO763196L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • C07D235/32Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Description

Fremgangsmåte til fremstilling av antelmintisk virksomme 2-karbalkoksyamino-5-(6) - f enyl-sulf onyloksy-benzimidazoler. Process for the production of anthelminthically active 2-carbalkoxyamino-5-(6)-phenyl-sulfonyloxy-benzimidazoles.

2-karbaloksy-amino-benzimidazolylderivater med alkyl, acyl-, fenoksy- og fenyltioester i 5(6)-stilling er kjent som antelmintica (P. Actor et al., Nature 215, 321 (1967), DOS 2.029.637, DOS 2.164.690, DOS 2.363.348). 2-Carbaloxy-amino-benzimidazolyl derivatives with alkyl, acyl, phenoxy and phenylthioesters in the 5(6) position are known as antelmintica (P. Actor et al., Nature 215, 321 (1967), DOS 2,029,637, DOS 2,164,690, DOS 2,363,348).

Oppfinnelsens gjenstand er en fremgangsmåte til fremstilling av antelmintisk virksomme 2-karbalkoksyamino-5(6)-fenyl-sulfonyloksy-benzimidazol med formel (1) The object of the invention is a method for the production of anthelminthically active 2-carbaloxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole with formula (1)

hvori R betyr alkyl med 1 til 4 C-atomer, R2og R betyr hver uavhengig av hverandre hydrogen, hydroksyl, alkoksy med 1 til 4 C-atomer, halogen, trifluormetyl, alkyl med 1 til 4 C-atomer, karbalkoksy med 1 til 4 C-atomer i alkoksyresten eller CN, idet fremgangsmåten erkarakterisert vedat et 2-karbalkoksyamin-5(6)-hydroksy-benzimidazol med formel (2), hvori har samme betydning som ovenfor omsettes i nærvær av en base med et benzensulfonsyrehalogenid med formel (3) wherein R means alkyl with 1 to 4 C atoms, R 2 and R each independently means hydrogen, hydroxyl, alkoxy with 1 to 4 C atoms, halogen, trifluoromethyl, alkyl with 1 to 4 C atoms, carboxyl with 1 to 4 C atoms in the alkoxy radical or CN, the method being characterized by a 2-carbaloxyamine-5(6)-hydroxy-benzimidazole of formula (2), in which has the same meaning as above, is reacted in the presence of a base with a benzenesulfonic acid halide of formula (3 )

hvori R2og R3har samme betydning som ovenfor og X betyr fluor, klor eller brom. For omsetningen er det foretrukket benzensulfonsyreklorid med formel (3). in which R2 and R3 have the same meaning as above and X means fluorine, chlorine or bromine. For the reaction, benzenesulfonic acid chloride with formula (3) is preferred.

Som alkylrester for substituentene R^, og R^kommer det i betraktning: metyl, etyl, propyl, isopropyl, butyl, sekundær-butyl, tertiær-butyl. Som alkoksygrupper for substituentene R^og R^kommer det i betraktning: metoksy, etoksy, propoksy, isopropoksy og butoksy. Som halogenatom for substituentene R2og R^kommer det i betraktning: fluor, klor, brom og jod. Som karbalkoksygrupper for substituentene R2og R^kommer det i betraktning:, karbometoksy, karbetoksy, karbopropoksy eller karbobu-toksy. As alkyl residues for the substituents R^, and R^ the following come into consideration: methyl, ethyl, propyl, isopropyl, butyl, secondary-butyl, tertiary-butyl. The following methoxy, ethoxy, propoxy, isopropoxy and butoxy are considered as alkoxy groups for the substituents R^ and R^. As a halogen atom for the substituents R 2 and R 2 the following are considered: fluorine, chlorine, bromine and iodine. Carbomethoxy groups for the substituents R 2 and R 4 come into consideration: carbomethoxy, carbethoxy, carbopropoxy or carbobutoxy.

Spesielt foretrukket er forbindelser med formel (1), hvori R^betyr metyl, etyl, propyl eller butyl, R2betyr hydrogen eller klor og R^betyr hydrogen, klor eller trifluormetyl. Particularly preferred are compounds of formula (1), in which R₂ means methyl, ethyl, propyl or butyl, R₂ means hydrogen or chlorine and R₂ means hydrogen, chlorine or trifluoromethyl.

Reaksjonsforløpet kan gjengis med følgende skjema The course of the reaction can be reproduced with the following form

For gjennomføring av reaksjonen suspenderer man et 2-karbalkoksy-amino-5(6)-hydroksy-benzimidazol med formel (2) i et aprotisk oppløsningsmiddel med et tertiært amin og tildrypper under omrøring en oppløsning av benzylensulfonsyrehalogenider med formel (3). Blandingen omrøres inntil omsetningen er avsluttet, idet man bestemmer tidspunktet hensiktsmessig ved hjelp av en To carry out the reaction, a 2-carbalkoxy-amino-5(6)-hydroxy-benzimidazole of formula (2) is suspended in an aprotic solvent with a tertiary amine and a solution of benzylene sulfonic acid halides of formula (3) is added dropwise while stirring. The mixture is stirred until the turnover is finished, the time being determined appropriately with the help of a

tynn sjiktokromatisk kontroll.thin layer chromatic control.

Som 2-karbalkoksyamino-5(6)-hydroksy-benzimidazol med formel (2) kommer det eksempelvis på tale As 2-carbalkoxyamino-5(6)-hydroxy-benzimidazole with formula (2) it is mentioned, for example

2-karbometoksyamino-2(6)-hydroksy-benzimidazol 2-karboetoksya-ino-5(6)-hydroksy-benzimidazol 2-carbomethoxyamino-2(6)-hydroxy-benzimidazole 2-carboethoxy-ino-5(6)-hydroxy-benzimidazole

2-karbisopropoksyamino-5(6)-hydroksy-benzimidazol 2-karbobutoksyamino-5(6)-hydroksy-benzimidazol 2-karbisobutoksyamino-5(6)-hydroksy-benzimidazol 2- karbotert.butoksyamino-5(6)-hydroksy-benzimidazol 2-carbisopropoxyamino-5(6)-hydroxy-benzimidazole 2-carbobutoxyamino-5(6)-hydroxy-benzimidazole 2-carbisobutoxyamino-5(6)-hydroxy-benzimidazole 2- carbotert.butoxyamino-5(6)-hydroxy-benzimidazole

Som aprotisk oppløsningsmiddel skal det nevnes aceton, tetrahydrofuran, dioksan, dietyleter, diisopropyleter, dimetylformamid, dimetylsulfoksyd, tetrametylurinstoff og liknende dipolare, aprotiske oppløsningsmidler. Acetone, tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, dimethylformamide, dimethylsulfoxide, tetramethylurea and similar dipolar, aprotic solvents should be mentioned as aprotic solvents.

Som baser kommer det på tale alkali- eller jordalkali-hydroksyder, -karbonater og -hydrogenkarbonater eller tertiære organiske baser. Som eksempler skal nevnes: natriumhydroksyd, natriumhydrogenkarbonat, natriumkarbonat, kaliumkarbonat, kalium-hydrogenkarbonat, trietylamin, pyridin og metyl-substituerte pyridiner. Bases include alkali or alkaline earth hydroxides, carbonates and hydrogen carbonates or tertiary organic bases. Examples include: sodium hydroxide, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium hydrogen carbonate, triethylamine, pyridine and methyl-substituted pyridines.

Som benzensulfonsyrehalogenider med formel (3) kommer eksempelvis i betraktning: As benzenesulfonic acid halides with formula (3) come into consideration, for example:

benzensulfonsyre-kloridbenzenesulfonic acid chloride

4-klor-benzensulfonsyre-klorid4-chloro-benzenesulfonic acid chloride

3- klor-benzensulfonsyre-klorid3-chloro-benzenesulfonic acid chloride

2- klor-benzensulfonsyre-klorid 2-chloro-benzenesulfonic acid chloride

2,5-diklor-benzensulfonsyre-klorid 2,5-dichlorobenzenesulfonic acid chloride

3.4- diklor-benzensulfonsyre-klorid 3.4-Dichlorobenzenesulfonic acid chloride

3.5- diklor-benzensulfonsyre-klorid 3.5-Dichlorobenzenesulfonic acid chloride

4- brom-benzensulfonsyre-klorid4-bromo-benzenesulfonic acid chloride

3- brom-benzensulfonsyre-klorid3-bromo-benzenesulfonic acid chloride

2- brom-benzensulfonsyre-klorid 2-bromo-benzenesulfonic acid chloride

4- metyl-benzensulfonsyre-klorid 4- Methyl-benzenesulfonic acid chloride

3- metyl-benzensulfonsyre-klorid 3- methyl-benzenesulfonic acid chloride

2-metyl-benzensulfonsyre-klorid 2-methyl-benzenesulfonic acid chloride

4- tert.butyl-benzensulfonsyre-klorid 4-tert.butyl-benzenesulfonic acid chloride

2,4-dimetyl-benzensulfonsyre-klorid 2,4-dimethylbenzenesulfonic acid chloride

2-klor-4-metyl-benzensulfonsyre-klorid 2-chloro-4-methyl-benzenesulfonic acid chloride

2-klor-6-metyl-benzensulfonsyre-klorid 2-chloro-6-methyl-benzenesulfonic acid chloride

3-klor-4-metyl-benzensulfonsyre-klorid 3-chloro-4-methyl-benzenesulfonic acid chloride

3- klor-6-metyl-benzensulfonsyre-klorid 3-chloro-6-methyl-benzenesulfonic acid chloride

4- klor-2-metyl-benzensulfonsyre-klorid 4-chloro-2-methyl-benzenesulfonic acid chloride

4-klor-3-metyl-benzensulfonsyre-klorid 4-chloro-3-methyl-benzenesulfonic acid chloride

4-klor-3,5-dimetyl-benzensulfonsyre-klorid 4-chloro-3,5-dimethyl-benzenesulfonic acid chloride

3- trifluormetyl-benzensulfonsyre-klorid 3-trifluoromethyl-benzenesulfonic acid chloride

4- metoksy-benzensulfonsyre-klorid4- methoxy-benzenesulfonic acid chloride

3-metoksy-benzensulfonsyre-klorid3-Methoxy-benzenesulfonic acid chloride

3- metoksy-benzensulfonsyre-klorid 3-Methoxy-benzenesulfonic acid chloride

4- propoksy-benzensulfonsyre-klorid 4- propoxy-benzenesulfonic acid chloride

4-isopropoksy-benzensulfonsyre-klorid 4-isopropoxy-benzenesulfonic acid chloride

4-butoksy-benzensulfonsyre-klorid 4-butoxy-benzenesulfonic acid chloride

4-isobutoksy-benzensulfonsyre-klorid4-isobutoxy-benzenesulfonic acid chloride

Reaksjonstemperaturområdet ligger mellom 0 og 60°C/fortrinnsvis mellom 15 og 30°C. Omsetningens hastighet avhenger av det anvendte benzensulfonsyreklorids reaksjonsevne således at varigheten kan variere fra få timer inntil en dag. The reaction temperature range is between 0 and 60°C/preferably between 15 and 30°C. The speed of the reaction depends on the reactivity of the benzene sulphonic acid chloride used, so that the duration can vary from a few hours to a day.

Reaksjonens fremmadskridning lar seg følge ved tynnsjikt-kromatografisk kontroll, idet man hensiktsmessig som adsorbens anvender kieselgel og som løpemiddel blandinger av kloroform, eddiksyreetylester og iseddik, fortrinnsvis i forhold-et 10:10:1. The progress of the reaction can be monitored by thin-layer chromatographic control, using silica gel as an adsorbent and mixtures of chloroform, ethyl acetate and glacial acetic acid as eluent, preferably in a ratio of 10:10:1.

Reaksjonsproduktene isoleres ved filtrering fra reaksjonsblandingen. Man får således: 2-karbometoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbometoksyamino-5(6)-(4-klor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3-klor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-klor-fenylsulfonyloksy)-benzimidazol The reaction products are isolated by filtration from the reaction mixture. One thus obtains: 2-carbomethoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-carbomethoxyamino-5(6)-(4-chloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3-chloro-phenylsulfonyloxy) -benzimidazole 2-carbomethoxyamino-5(6)-(2-chloro-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(2,5-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3,4-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3,5-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-brom-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2,5-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3,4-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-( 3,5-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(4-bromo-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(3-brom-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-brom-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-tert.butyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(3-bromo-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(2-bromo-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(4-methyl- phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3-methyl-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(2-methyl-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-( 4-tert.butyl-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(2-klor-4-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2-chloro-4-methyl-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(2-klor-6-metyl-fenylsulfonyloksy)benzimidazol 2-carbomethoxyamino-5(6)-(2-chloro-6-methyl-phenylsulfonyloxy)benzimidazole

2-karbometoksyamino-5(6)-(3-klor-4-metyl-fenylsulfonyloksy)-benz-imidazol 2-carbomethoxyamino-5(6)-(3-chloro-4-methyl-phenylsulfonyloxy)-benz-imidazole

2-karbometoksyamino-5(6)-(3-klor-6-metyl-fenylsulfonyloksy)benzimidazol 2-carbomethoxyamino-5(6)-(3-chloro-6-methyl-phenylsulfonyloxy)benzimidazole

2-karbometoksyamino-5(6)-(4-klor-2-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-2-methyl-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-klor-3-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-3-methyl-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-klor-3,5-dimetyl-fenylsulfonyloksy-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-3,5-dimethyl-phenylsulfonyloxy-benzimidazole

2-karbometoksyamino-5 (6) - (3-tr i f luormetyl-f enylsulf ony loksy)-benz-;imidaz".Q.l7J::L 2-carbomethoxyamino-5 (6)-(3-trifluoromethyl-phenylsulfonyloxy)-benz-;imidaz".Q.l7J::L

2-karbometoksyamino-5(6)-(4-metoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-methoxy-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(2-metoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2-methoxy-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-propoksy-fenylsulfonyloksy)-benzimidazol 2-Carbomethoxyamino-5(6)-(4-propoxy-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-isopropoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-isopropoxy-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-butoksy-fenylsulfonyloksy)-benzimidazol 2-Carbomethoxyamino-5(6)-(4-butoxy-phenylsulfonyloxy)-benzimidazole

2-karbometoksyamino-5(6)-(4-isobutoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-isobutoxy-phenylsulfonyloxy)-benzimidazole

2-karbetoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbopropoksy-5(6)-fenylsulfonyloksy-benzimidazol 2-karbisopropoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbobutoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbisobutoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2- karbotert.butoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-Carbethoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbopropoxy-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbisopropoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbobutoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2- carbisobutoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2- carbotert.butoxyamino-5(6)-phenylsulfonyloxy-benzimidazole

Som utgangsmaterial tjener 2-karbalkoksyamino-5(6)-hydroksy-benzimidazol med formel (2) som fremstilles etter kjente fremgangsmåter/ -sammenliknet DOS 2.164.690. Således omsetter man 3- nitro-4-amino-fenol med benzoylklorid til benzosyre-3-nitro- 4-amino-fen^lester, hydrerer denne forbindelse med Raney-nikkel til 3,4-diaminoderivatet og omsetter dette med S-metyl-tiourin-stoffkarboksylat til 2-karbalkoksyamino-5-benzoyloksy-benzimidazol, hvorav med fortynnet natronlut fås hydroksyforbindelsen med formel (2 ) . 2-carbaloxyamino-5(6)-hydroxy-benzimidazole with formula (2) which is produced according to known methods/ - compared to DOS 2,164,690 serves as starting material. Thus, 3-nitro-4-amino-phenol is converted with benzoyl chloride into benzoic acid 3-nitro-4-amino-phenol ester, this compound is hydrogenated with Raney nickel to the 3,4-diamino derivative and this is reacted with S-methyl- thiourea carboxylate to 2-carbaloxyamino-5-benzoyloxy-benzimidazole, from which with diluted caustic soda the hydroxy compound with formula (2) is obtained.

2-karbalkoksyamino-5(6)-fenylsulfonyloksy-benzi-imidazolet ifølge oppfinnelsen er verdifulle kjemoterapeutica og egner seg til bekjempelse av parasitære sykdommer hos mennes-ker og dyr som fra helminter og leverigler. The 2-carbaloxyamino-5(6)-phenylsulfonyloxy-benzi-imidazole according to the invention are valuable chemotherapeutics and are suitable for combating parasitic diseases in humans and animals such as from helminths and liver leeches.

De er spesielt virksomme for et stort antall helminter, f.eks. Haemonchus, Trichostrongylus, Ostertagia, Strongyloides, Cooperia, Chabertia, Oesophagostomum, Hyostron-gylus, Ankylostoma, Askaris og Heterakis. Spesielt utpreget er virkningen overfor mage-tarm-Strongylider hvorav fremfor alt drøvtyggere angripes. Dyrenes angrep av disse parasitter fører til store økonomiske skader hvor forbindelsene ifølge oppfinnelsen finner spesiell anvendelse i veterinærmidler. They are particularly effective for a large number of helminths, e.g. Haemonchus, Trichostrongylus, Ostertagia, Strongyloides, Cooperia, Chabertia, Oesophagostomum, Hyostron-gylus, Ankylostoma, Askaris and Heterakis. Particularly pronounced is the effect against gastrointestinal Strongylides, of which above all ruminants are attacked. The animals' attack by these parasites leads to great economic damage, where the compounds according to the invention find special use in veterinary medicines.

Virksomme stoffer med formel (1) administreres alt etter tilfelles stilling i doseringer mellom 0,5 og 50 mg pr./kg legemsvekt i 1 til 14 dager. Active substances with formula (1) are administered, depending on the situation of the case, in dosages between 0.5 and 50 mg per kg of body weight for 1 to 14 days.

Til oral applikasjon kommer det i betraktning tabibetter, drageer, kapsler, pulver, granulater eller pastaer som inneholder de virksomme stoffer sammen med vanlig hjelpe-eller bærestoffer som stivelse, cellulosepulver, talkum, magnesiumstearat, sukker, gelatiner, kalciumkarbonat, finfordelt kieselsyre, karboksymetylcellulose eller liknende stoffer. For oral application, tablets, dragees, capsules, powders, granules or pastes containing the active substances together with usual auxiliary or carrier substances such as starch, cellulose powder, talc, magnesium stearate, sugar, gelatins, calcium carbonate, finely divided silicic acid, carboxymethyl cellulose or similar substances.

Til parenteral applikasjon kommer det i betraktning oppløsninger, f.eks. oljeaktige oppløsninger som fremstilles under anvendelse av sesamolje, ricinusolje eller syntetiske triglycerider, eventuelt med en tilsetning av tokoferol som antioksydans og/eller under anvendelse av grenseflateaktive stoffer som sorbitanfettsyreestere. Dertil kommer vandig sus-pensjoner i betraktning som fremstilles under anvendelse av . etoksylerte sorbitan-fettsyreestere eventuelt under tilsetning av fortykningsmidler, som polyetylenglykol eller karboksymetylcellulose. For parenteral application solutions are considered, e.g. oily solutions that are prepared using sesame oil, castor oil or synthetic triglycerides, optionally with the addition of tocopherol as an antioxidant and/or using surfactants such as sorbitan fatty acid esters. In addition, aqueous suspensions are taken into account which are produced using . ethoxylated sorbitan fatty acid esters, optionally with the addition of thickeners, such as polyethylene glycol or carboxymethyl cellulose.

Konsentrasjonen av de virksomme stoffer ifølge oppfinnelsen i de dermed fremstilte preparater ligger fortrinnsvis for bruk som veterinærlegemiddel mellom 2 og 20 vekt-%,for bruk som humanlegemiddel ligger konsentrasjonen av de virksomme stoffer fortrinnsvis mellom 20 og 80 vekt-%. The concentration of the active substances according to the invention in the thus prepared preparations is preferably for use as a veterinary medicine between 2 and 20% by weight, for use as a human medicine the concentration of the active substances is preferably between 20 and 80% by weight.

For å fastslå virkningen av forbindelsene ifølge oppfinnelsen ble det gjennomført kromatografiske undersøkelser på ca. 30 kg tunge sauelam, som eksperimentelt var blitt infisert med larver av Trichostrongylus colubriformis resp. Haemonchus contortus. Forsøksdyrene ble holdt i flislagte bokser som daglig ble renset grundig. Etter forløpet av prepatenstiden (tiden mellom infeksjon og kjønnsmoden etter parasitten med begynnende utskillelse av egg eller larver) ble bestemt til modifiserte McMaster-fremgangsmåten ifølge Wetzel (Tierårztliche Umschau 6, 209 - 210 (1951)) eggtaller pr. gram avføring. Umiddelbart deretter ble det foretatt behandling av sauene (vanligvis 4 til 8 dyr pr. virksomt stoff, minst imidlertid 2). Dyrene ble applisert doseringene av fremgangsmåteproduktene som suspensjon i hver gang 10 ml av en l%ig tylose-suspensjon. Hver gang på In order to determine the effect of the compounds according to the invention, chromatographic examinations of approx. 30 kg sheep lambs, which had been experimentally infected with larvae of Trichostrongylus colubriformis resp. Haemonchus contortus. The experimental animals were kept in tiled boxes which were thoroughly cleaned daily. After the course of the prepatent period (the time between infection and sexual maturity after the parasite with the beginning of excretion of eggs or larvae) was determined according to the modified McMaster method according to Wetzel (Tierårztliche Umschau 6, 209 - 210 (1951)) egg numbers per grams of stool. Immediately thereafter, the sheep were treated (usually 4 to 8 animals per active substance, at least 2, however). The animals were administered the dosages of the process products as a suspension in each time 10 ml of a 1% tylose suspension. Every time on

den 7., 14. og 28. dag etter behandlingen ble det igjen etter ovennevnte fremgangsmåte . f astslåttcejgtall pr. gr. avføring og dens prosentielle nedgang regnes sammenliknet utgangsverdien før behandling. on the 7th, 14th and 28th day after the treatment, it was again according to the above procedure. f estimated numbers per Gr. faeces and its percentage decrease are calculated compared to the starting value before treatment.

Nedenstående tabell gjengir virkningen av noen forbindelser ifølge oppfinnelsen i disse forsøk. The table below reproduces the effect of some compounds according to the invention in these experiments.

Fremgangsmåteproduktene er ikke bare utmerket virksomme oralt applisert, men virker også parenteralt i doseringer ned til 2 mg/kg. Dermed er de langt overlegne sammenlignbare benzimidazolderivater, spesielt alle kjente 5(6)-substituerte 2-benzimidazol-karbaminater. The method products are not only excellently effective orally applied, but also work parenterally in dosages down to 2 mg/kg. Thus, they are far superior to comparable benzimidazole derivatives, especially all known 5(6)-substituted 2-benzimidazole carbamates.

Eksempel 1.Example 1.

Man suspenderer 5,15 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol i 100 ml aceton og tilsetter 3,5 ml trietylamin. Under kraftig omrøring lar man ved værelsestemperatur en oppløsning av 4,4 g benzensulfonsyreklorid i 20 ml aceton til-dryppe og omrører i 10 timer idet suspensjonens konsistens tydelig endrer seg. Den blir i første rekke tyntflytende og igjen etter hvert tykk. Etter avkjøling frafiltrerer man de faste bestanddeler, vasker i rekkefølge med aceton, vann og metanol og tørker på dampbad. 5.15 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole are suspended in 100 ml of acetone and 3.5 ml of triethylamine are added. With vigorous stirring, a solution of 4.4 g of benzenesulfonic acid chloride in 20 ml of acetone is added dropwise at room temperature and stirred for 10 hours, as the consistency of the suspension clearly changes. It first becomes runny and then gradually thickens. After cooling, the solid components are filtered off, washed in sequence with acetone, water and methanol and dried in a steam bath.

Til rensning omkrystalliseres råproduktet fra iseddik/metanol. Utbyttet av 2-karbometoksyamino-5(6)-fenylsul-fonyl-oksy-benzimidazol utgjør 6,2 g av spaltningspunkt 242°C. Den tynnsjikt-kromatografiske kontroll av reaksjonsblandingen på kieselgel med en blanding av 10 ml kloroform, 10 ml eddiksyreetylester og 1 ml iseddik som løpemiddel viser at flekken av ut-gangsmaterialet er forsvunnet og i dets sted er det trått denne av produksjonsproduktet med høyere R F-verdi. For purification, the crude product is recrystallized from glacial acetic acid/methanol. The yield of 2-carbomethoxyamino-5(6)-phenylsulfonyl-oxy-benzimidazole amounts to 6.2 g of decomposition point 242°C. The thin-layer chromatographic control of the reaction mixture on silica gel with a mixture of 10 ml of chloroform, 10 ml of acetic acid ethyl ester and 1 ml of glacial acetic acid as eluent shows that the stain of the starting material has disappeared and in its place there is this of the production product with a higher R F- value.

Analogt vil man under anvendelse av ekvivalente mengder av de tilsvarende benzensulfonsyreklorider av 5,15 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol og 2) 5,3 g 4-klor-benzensulfonsyreklorid få Analogously, using equivalent amounts of the corresponding benzenesulfonic acid chlorides, 5.15 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole and 2) 5.3 g of 4-chlorobenzenesulfonic acid chloride will be obtained

6,8 g 2-karbometoksyamino-5(6)-(4-klor-fenylsulfonyloksy)-bensimidazol med smeltepunkt 230°C (under spaltning) 6.8 g of 2-carbomethoxyamino-5(6)-(4-chloro-phenylsulfonyloxy)-benzimidazole with melting point 230°C (under decomposition)

3) 5,3 g 3-klor-benzensulfonsyreklorid få3) Get 5.3 g of 3-chloro-benzenesulfonic acid chloride

6,8 g 2-karbometoksyamino-5(6)-(3-klor-fenylsulfonyloksy)-benzimidazol med smeltepunkt 250°C (under spaltning) 6.8 g of 2-carbomethoxyamino-5(6)-(3-chloro-phenylsulfonyloxy)-benzimidazole with melting point 250°C (under decomposition)

4) 6,15 g 3,4-diklor-benzensulfonsyreklorid få4) Get 6.15 g of 3,4-dichlorobenzenesulfonic acid chloride

7,4 g 2-karbometoksyamino-5(6)-(3,4-diklor-fenylsulfonyloksy)-benzimidazol med smeltepunkt 255°C (under spaltning) 7.4 g of 2-carbomethoxyamino-5(6)-(3,4-dichloro-phenylsulfonyloxy)-benzimidazole with melting point 255°C (under decomposition)

5) 6,15 g 3,5-diklor-benzensulfonsyre-klorid få5) Get 6.15 g of 3,5-dichlorobenzenesulfonic acid chloride

7,3 g 2-karbometoksyamino-5(6)-(3,5-diklor-fenylsulfonyl-oksy) -benzimidazol . med smltepunkt 280°C (under spaltning). 7.3 g of 2-carbomethoxyamino-5(6)-(3,5-dichloro-phenylsulfonyl-oxy)-benzimidazole. with melting point 280°C (under decomposition).

6) 6,4 g 3-brom-benzensulfonsyreklorid få6) Get 6.4 g of 3-bromobenzenesulfonic acid chloride

7,6 g 2-karbometoksyamino-5(6)-(3-brom-fenylsulfonyloksy)-benzimidazol med smeltepunkt 242°C (under spaltning). 7.6 g of 2-carbomethoxyamino-5(6)-(3-bromo-phenylsulfonyloxy)-benzimidazole with melting point 242°C (under decomposition).

7) 4,8 g 4-metyl-benzensulfonsyreklorid få7) Get 4.8 g of 4-methyl-benzenesulfonic acid chloride

6,4 g 2-karbometoksyamino-5(6)-(4-metyl-fenylsulfonyloksy)-benzimidazol med smeltepunkt 237°C (under spaltning). 6.4 g of 2-carbomethoxyamino-5(6)-(4-methyl-phenylsulfonyloxy)-benzimidazole with melting point 237°C (under decomposition).

8) 4,8 g 3-metyl-benzensulfonsyreklorid få8) Get 4.8 g of 3-methyl-benzenesulfonic acid chloride

6,4 g 2-karbometoksyamino-5(6)-(3-metyl-fenylsulfonyloksy)-benzimidazol med smeltepunkt 250°C (under spaltning). 6.4 g of 2-carbomethoxyamino-5(6)-(3-methyl-phenylsulfonyloxy)-benzimidazole with melting point 250°C (under decomposition).

9) 6,1 g 3-trifluormetyl-benzensulfonsyreklorid få9) Get 6.1 g of 3-trifluoromethyl-benzenesulfonic acid chloride

7,4 g 2-karbometoksyamino-5(6)-(3-trifluormetyl-fenylsulfonyl-oksy) -benzimidazol med smeltepunkt 215°C (under spaltning). 7.4 g of 2-carbomethoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyl-oxy)-benzimidazole with melting point 215°C (under decomposition).

Man vil under anvendelse av 6,1 g 3-trifluormetyl-benzensulf onsyreklorid og One will, using 6.1 g of 3-trifluoromethyl-benzenesulfonic acid chloride and

10) 5,5 g 2-karbetoksyamino-5(6)-hydroksy-benzimidazol få10) 5.5 g of 2-carbethoxyamino-5(6)-hydroxy-benzimidazole get

7,7 g 2-karbetoksyamino-5(6)-(3-trifluormetyl-fenylsulfonyl-oksy) -benzimidazol med smeltepunkt 227°C (under 7.7 g of 2-carbethoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyl-oxy)-benzimidazole with a melting point of 227°C (below

spaltning).cleavage).

11) 5,9 g 2-karbispropoksyamino-5(6)-hydroksy-benzimidazol få 8,0 g 2-karbispropoksyamino-5(6)-(3-trifluormetyl-fenylsul-fonyloksy) -benzimidazol med smeltepunkt 205°C (under 11) 5.9 g of 2-carbispropoxyamino-5(6)-hydroxy-benzimidazole obtain 8.0 g of 2-carbispropoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyloxy)-benzimidazole with a melting point of 205°C (below

spaltning)cleavage)

12) 6,2 g 2-karbisbutoksyamino-5(6)-hydroksy-benzimidazol få 8,2 g 2-karbisbutoksyamino-5(6)-(3-trifluormetyl-fenylsul-fonyloksy) -benzimidazol med smeltepunkt 243°C (under 12) 6.2 g of 2-carbisbutoxyamino-5(6)-hydroxy-benzimidazole obtain 8.2 g of 2-carbisbutoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyloxy)-benzimidazole with a melting point of 243°C (below

spaltning)cleavage)

13) 5,1 g 3-cyano-benzosulfonsyreklorid få13) Get 5.1 g of 3-cyano-benzosulfonic acid chloride

6,7 g 2-karbometoksyamino-5(6)-(3-cyano-fenylsulfonyloksy)-benzimidazol med smeltepunkt 275°C (under spaltning) 6.7 g of 2-carbomethoxyamino-5(6)-(3-cyano-phenylsulfonyloxy)-benzimidazole with melting point 275°C (under decomposition)

For fremstilling av det som utgangsmateriale anvendte 2-karbometoksy-amino-5(6)-hydroksy-benzimidazol blandes 56 g S-metyltiourinstoffsulfat i 90 ml vann med 26 ml klormaursyre-metylester og ved en temperatur under 20°C tildryppes 116 g 25%ig natronlut. Man etteromrører ennå i en halv time og tilsetter deretter en oppløsning som var blitt fremstilt ved hyd-rering av 51,6 g benzosyre-3-nitro-4-amino-fenylester i 250 ml iseddik med Raney-nikkel og frafiltrering av katalysatoren. Man tilsetter 300 ml iseddik, 100 ml vann og 100 ml metanol og koker 2 timer under tilbakeløp. Etter avkjøling isolerer man det utfelte 2-karbometoksyamino-5(6)-benzoyloksy-benzimidazol i et ut-bytte på 41 g med smeltepunkt 280°C (under spaltning). For the preparation of the 2-carbomethoxy-amino-5(6)-hydroxy-benzimidazole used as starting material, 56 g of S-methylthiourea sulphate is mixed in 90 ml of water with 26 ml of chloroformic acid methyl ester and at a temperature below 20°C, 116 g of 25% ig sodium lye. Stirring is continued for half an hour and a solution is then added which had been prepared by hydrogenating 51.6 g of benzoic acid 3-nitro-4-amino-phenyl ester in 250 ml of glacial acetic acid with Raney nickel and filtering off the catalyst. 300 ml of glacial acetic acid, 100 ml of water and 100 ml of methanol are added and boiled for 2 hours under reflux. After cooling, the precipitated 2-carbomethoxyamino-5(6)-benzoyloxy-benzimidazole is isolated in a yield of 41 g with a melting point of 280°C (under decomposition).

Det således dannede 2-karbometoksyamino-5(6)-benzoyl-oksy-benzimidazol omrøres i 5 minutter i en blanding av 400 ml metanol og 400 ml 2n natronlut, oppløsningen filtreres, nøytrali-seres med iseddik og inndampes i vakuum. Residuet blandes med 100 ml vann, det utfelte faste stoff frasuges og utvaskes med metanol og diisopropyleter. Etter omkrystallisering frå iseddik/ metanol 1:1 får man 21 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol med smeltepunkt 305°C (under spaltning). The 2-carbomethoxyamino-5(6)-benzoyl-oxy-benzimidazole thus formed is stirred for 5 minutes in a mixture of 400 ml of methanol and 400 ml of 2N caustic soda, the solution is filtered, neutralized with glacial acetic acid and evaporated in vacuo. The residue is mixed with 100 ml of water, the precipitated solid is sucked off and washed out with methanol and diisopropyl ether. After recrystallization from glacial acetic acid/methanol 1:1, 21 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole with a melting point of 305°C (under decomposition) is obtained.

Claims (1)

Fremgangsmåte til fremstilling av 2-karbalkoksy-amino-5(6)-fenyl-sulfonyloksy-benzimidazoler med formel (1)Process for the preparation of 2-carbalkoxy-amino-5(6)-phenyl-sulfonyloxy-benzimidazoles with formula (1) hvori R^ betyr alkyl med 1 til 4 C-atomer, R^ og R^ betyr hver uavhengig av hverandre hydrogen, hydroksyl, alkoksy med 1 til 4 C-atomer, halogen, trifluormetyl, alkyl med 1 til 4 C-atomer, karbalkoksy med 1 til 4 C-atomer i alkoksy-resten eller CN, karakterisert ved at et 2-karbalkoksyamino-5(6)- hydroksy-benzimidazol med formel (2) in which R^ means alkyl of 1 to 4 C atoms, R^ and R^ each independently of the other means hydrogen, hydroxyl, alkoxy of 1 to 4 C atoms, halogen, trifluoromethyl, alkyl of 1 to 4 C atoms, carbaloxy with 1 to 4 C atoms in the alkoxy residue or CN, characterized in that a 2-carbalkoxyamino-5(6)- hydroxybenzimidazole of formula (2) hvori R1 har samme betydning som i formel (1) omsettes i nærvær av en base med et benzensulfonsyrehalogenid med formel (3) wherein R1 has the same meaning as in formula (1) is reacted in the presence of a base with a benzenesulfonic acid halide of formula (3) hvori R2 og R3 har samme betydning som i formel (1) og X betyr fluor, klor eller brom.wherein R2 and R3 have the same meaning as in formula (1) and X means fluorine, chlorine or bromine.
NO763196A 1975-09-19 1976-09-17 PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES. NO763196L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752541752 DE2541752A1 (en) 1975-09-19 1975-09-19 ANTHELMINTHICALLY ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULFONYLOXY- BENZIMIDAZOLE AND METHOD FOR THEIR PRODUCTION

Publications (1)

Publication Number Publication Date
NO763196L true NO763196L (en) 1977-03-22

Family

ID=5956862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO763196A NO763196L (en) 1975-09-19 1976-09-17 PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES.

Country Status (12)

Country Link
AT (1) AT358575B (en)
CA (1) CA1069909A (en)
CH (1) CH619938A5 (en)
DE (1) DE2541752A1 (en)
DK (1) DK141550C (en)
ES (1) ES451497A2 (en)
FI (1) FI762653A (en)
GR (1) GR60799B (en)
HU (1) HU172484B (en)
NO (1) NO763196L (en)
PT (1) PT65607B (en)
SE (1) SE7610310L (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435418A (en) * 1982-12-13 1984-03-06 Smithkline Beckman Corporation 5-Phenylethenylbenzimidazoles
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
FR2868421B1 (en) 2004-04-01 2008-08-01 Aventis Pharma Sa NOVEL BENZOTHIAZOLES AND THEIR USE AS MEDICAMENTS
FR2891273B1 (en) 2005-09-27 2007-11-23 Aventis Pharma Sa NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE, IN PARTICULAR AS CMET INHIBITORS

Also Published As

Publication number Publication date
DK141550C (en) 1980-10-06
CA1069909A (en) 1980-01-15
HU172484B (en) 1978-09-28
SE7610310L (en) 1977-03-20
ATA690876A (en) 1980-02-15
FI762653A (en) 1977-03-20
PT65607B (en) 1978-05-10
AT358575B (en) 1980-09-25
DK141550B (en) 1980-04-21
DK419876A (en) 1977-03-20
CH619938A5 (en) 1980-10-31
GR60799B (en) 1978-08-30
DE2541752A1 (en) 1977-03-24
ES451497A2 (en) 1977-12-01
PT65607A (en) 1976-10-01

Similar Documents

Publication Publication Date Title
SU602118A3 (en) Method of producing benzimidazole derivatives or salts thereof
US3954791A (en) Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers
NO834773L (en) SUBSTITUTED PHENYL SULPHONYLOXYBENZIMIDAZOLE CARBAMINATES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS A MEDICINE
NO763196L (en) PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES.
NO140592B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXYAMINO-BENZIMIDAZOLYL-5- (6) -SULPHONIC ACID PHENYLES
NO140591B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXY-AMINO-5 (6) -PHENYL SULPHONYLOXY-BENZIMIDAZOLES
NO743436L (en)
US4010272A (en) Anthelmintically active basically substituted 2-carbalkoxy-amino-benzimidazolyl-5(6)-phenyl ethers and -ketones
NO120370B (en)
JPS6216469A (en) 2-substituted cycloheptoimidazole derivative, antiulcer agent and production thereof
US3984561A (en) Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers and method for using the same
CA1056828A (en) Preparation of 2,1,4-benzothiadiazine derivatives
KR790001340B1 (en) Process for preparing 2-carboalkoxy amino-5(6)-phenyl sulfonyloxy benzimidazoles
JPS5914027B2 (en) 2-Carbalkoxyamino-5(6)-phenylsulfonyloxy-benzimidazole compound
US4069325A (en) 3-Carbalkoxyamino-1H-2,1,4-benzothiadiazine derivatives
NO751871L (en)
JPS5914026B2 (en) 2-Carbalkoxyamino-benzimidazolyl-5(6)-sulfonic acid-phenyl ester compound
KR790001341B1 (en) Process for preparing 2-carboalkoxy amino benzimi-dazolyl-5 (6)-sulfonic acid phenyl esters
KR910008938B1 (en) Process for preparing of pyridine derivertes
NO763197L (en) PROCEDURES FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXYAMINO-BENZIMIDAZOLE DERIVATIVES.
CS196284B2 (en) Method of producing phenylesters of 2-alkoxycarbonyl aminobenzimidazol-5/6/-ylsulphonic acid
NO763194L (en) PROCEDURES FOR THE PREPARATION OF ANTELMINTIC ACTIVITY BASIC SUBSTITUTED 2-CARBALCOXYAMINO-BENZIMIDAZOLYL-5 (6) PHENYLETERS AND KETONES.
JPS62175481A (en) Novel sulfoxide derivative and production thereof
NO136711B (en)
CS196280B2 (en) Method of producing 2-alkoxycarbonyl-amino-5/6/-phenylsulphonyl- oxybenzimidazoles